Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.19 +0.4%	$1.21	$0.64 ▼ $2.92	$47.60M	-0.73	53,681 shs	6,823 shs
ENGN enGene	$4.32 +10.5%	$3.64	$2.65 ▼ $11.00	$220.77M	-0.41	99,971 shs	120,697 shs
EPRX Eupraxia Pharmaceuticals	$5.28 +1.5%	$5.21	$2.20 ▼ $6.20	$189.83M	1.5	11,043 shs	3,916 shs
MDWD MediWound	$17.60 +1.2%	$19.29	$14.14 ▼ $22.50	$190.28M	0.21	75,790 shs	79,455 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-5.18%	-31.81%	+81.96%	-6.30%
ENGN enGene	0.00%	+17.39%	+17.07%	+1.89%	-29.76%
EPRX Eupraxia Pharmaceuticals	0.00%	-0.75%	-4.69%	+36.43%	+97.75%
MDWD MediWound	0.00%	-2.76%	-15.63%	-13.60%	-6.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.2125 of 5 stars	3.5	3.0	3.6	0.8	1.3
ENGN enGene	3.3247 of 5 stars	3.5	5.0	1.7	2.5	0.6
EPRX Eupraxia Pharmaceuticals	1.9681 of 5 stars	3.6	1.0	1.6	0.0	0.6
MDWD MediWound	1.4375 of 5 stars	3.4	1.0	0.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	152.10% Upside
ENGN enGene	3.00	Buy	$23.29	439.02% Upside
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	108.33% Upside
MDWD MediWound	2.80	Moderate Buy	$32.25	83.24% Upside

Current Analyst Ratings Breakdown

Latest BRNS, EPRX, MDWD, and ENGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/19/2025	MDWD MediWound	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.21	N/A	N/A	$2.54 per share	0.47
ENGN enGene	N/A	N/A	N/A	N/A	$5.35 per share	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	($0.30) per share	N/A
MDWD MediWound	$19.86M	9.58	N/A	N/A	$1.86 per share	9.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	9/10/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.85	N/A	N/A	N/A	N/A	-367.73%	-126.38%	11/6/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.64	N/A	N/A	N/A	-142.18%	-96.71%	-39.73%	N/A

Latest BRNS, EPRX, MDWD, and ENGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	Q3 2025	ENGN enGene	-$0.5084	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/12/2025	Q2 2025	EPRX Eupraxia Pharmaceuticals	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ENGN enGene	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
ENGN enGene	0.09	12.66	12.66
EPRX Eupraxia Pharmaceuticals	N/A	8.72	8.72
MDWD MediWound	N/A	1.48	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
ENGN enGene	64.16%
EPRX Eupraxia Pharmaceuticals	N/A
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
ENGN enGene	10.40%
EPRX Eupraxia Pharmaceuticals	N/A
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	36.02 million	N/A
ENGN enGene	31	51.10 million	45.79 million	N/A
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
MDWD MediWound	80	10.81 million	9.81 million	Optionable

BRNS, EPRX, MDWD, and ENGN Headlines

Recent News About These Companies

MediWound (NASDAQ:MDWD) Downgraded to "Hold" Rating by Zacks Research

August 23 at 7:37 AM | marketbeat.com

MediWound to Present at the H.C. Wainwright 27th Annual Global ...

August 22 at 11:34 AM | morningstar.comM

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

August 20, 2025 | globenewswire.com

MediWound Executives Purchase Shares, Signaling Confidence

August 19, 2025 | msn.com

MediWound (NASDAQ:MDWD) Posts Quarterly Earnings Results, Misses Expectations By $0.68 EPS

August 18, 2025 | marketbeat.com

Craig-Hallum Sticks to Their Buy Rating for Mediwound (MDWD)

August 17, 2025 | theglobeandmail.com

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) Second-Quarter Report

August 17, 2025 | finance.yahoo.com

MediWound reports Q2 EPS ($1.23), consensus (57c)

August 14, 2025 | msn.com

MediWound Revenue Jumps 43% in Q2

August 14, 2025 | aol.comA

MediWound Reports Q2 2025 Financial Results and Strategic Updates

August 14, 2025 | msn.com

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

August 14, 2025 | seekingalpha.com

MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates

August 14, 2025 | zacks.com

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | globenewswire.com

MediWound Q2 2025 Earnings Preview

August 13, 2025 | msn.com

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

August 13, 2025 | globenewswire.com

MediWound (MDWD) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

MediWound Ltd. to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 14

August 4, 2025 | quiverquant.comQ

MediWound to Report Second Quarter 2025 Financial Results

August 4, 2025 | globenewswire.com

Here's What Could Help MediWound (MDWD) Maintain Its Recent Price Strength

July 24, 2025 | msn.com

MediWound Ltd. (NASDAQ:MDWD) is definitely on the radar of institutional investors who own 42% of the company

July 7, 2025 | finance.yahoo.com

MediWound Ltd. (MDWD) latest stock news and headlines - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, EPRX, MDWD, and ENGN Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.19 +0.01 (+0.42%)

Closing price 08/22/2025 03:50 PM Eastern

Extended Trading

$1.21 +0.02 (+1.68%)

As of 08/22/2025 04:54 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

enGene NASDAQ:ENGN

$4.32 +0.41 (+10.49%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.24 -0.08 (-1.85%)

As of 08/22/2025 07:33 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.28 +0.08 (+1.54%)

Closing price 08/22/2025 03:50 PM Eastern

Extended Trading

$5.52 +0.25 (+4.64%)

As of 08/22/2025 07:42 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

MediWound NASDAQ:MDWD

$17.60 +0.21 (+1.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.58 -0.02 (-0.11%)

As of 08/22/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time